S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

KTTA Pasithea Therapeutics Corporation

5.30

0.00 (0.00%)

Pre Market

Last Updated: 03:05:40

Delayed by 15 minutes

Form ARS - Annual Report to Security Holders

Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics Corporation News

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
Thursday 13 June 2024 (2 weeks ago) • GlobeNewswire Inc.

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
Tuesday 28 May 2024 (4 weeks ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Monday 29 April 2024 (2 months ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Wednesday 24 April 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (4 months ago) • Edgar (US Regulatory)

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Tuesday 13 February 2024 (4 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 18 January 2024 (5 months ago) • Edgar (US Regulatory)

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Monday 8 January 2024 (6 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 2 January 2024 (6 months ago) • Edgar (US Regulatory)

More Pasithea Therapeutics Corporation News Articles

Thunder Bridge Captial P...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions